Literature DB >> 18832431

A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD).

J R Davidson1, W Zhang, K M Connor, J Ji, K Jobson, Y Lecrubier, A C McFarlane, D J Newport, D J Nutt, D N Osser, D J Stein, Z N Stowe, O Tajima, M Versiani.   

Abstract

Generalised anxiety disorder (GAD) is defined as excessive and uncontrollable worry and anxiety about everyday life situations. It is a chronic disorder, and is associated with substantial somatisation, high rates of comorbid depression and other anxiety disorders, and significant disability. The evidence base for pharmacotherapy and psychotherapy has continued to grow, and a wide range of drug choices for GAD now exists. Current guidelines for GAD generally restrict themselves to presentation of the evidence for various treatments, which, as a result, generally do not offer detailed discussion or recommendation of strategies beyond the first level of treatment, or take into account the individual circumstances of the patient. Thus, there is a lack of algorithm-based treatment guidelines for GAD. Our aim is, therefore, to present an algorithm for the psychopharmacologic management of GAD, intended for all clinicians who treat patients with GAD, where issues of pharmacotherapy are under consideration. We also hope that these GAD algorithms and other guidelines can help to identify high-priority areas that need further study. In this algorithm, we provide a sequenced approach to the pharmacotherapy of GAD, taking into account salient symptomatology and comorbidity, levels of evidence and extent of response. Special issues, including comorbidity, insomnia, suicidality, substance abuse, treatment adherence, pregnancy and lactation, cross-cultural issues, use of medication in the elderly, psychosocial treatment and dosing issues are also addressed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832431      PMCID: PMC2951594          DOI: 10.1177/0269881108096505

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


Dora Kohen trained both in neurology and psychiatry. She contributed enormously to British medicine. Sadly she died prematurely. In so many ways Dora was a breath of fresh air, in both clinical and academic circles. She frequently challenged orthodox accepted viewpoints but did so in a manner that was always friendly and never condescending. She had a capacity to view the obvious from a not so obvious perspective. When she put forward a view she made others sit up and take note. She ascribed to the philosophy that nothing should be accepted, simply because it always had been. If something could be done in a more effective, but less traditional manner, then so be it. She had a resourceful, robust personality and always stood up for what she believed. In a conservative profession, as is medicine, that is not always an easy path, but Dora never took the path of least resistance. She always took the road she considered was right. There were occasions when diverting and turning a blind eye would have avoided personal stress, but selling-out was not part of her agenda. As a clinician with a background in both neurology and psychiatry she was superb. Patients loved her and she was always prepared to go the extra mile on their behalf. She had clinical skill few could match. If one was to attribute a single characteristic to Dora it would be optimism. Whatever difficulties she faced, right to the end, she took an optimistic viewpoint. She always believed that things would work out for the best. To her husband Karabey and her beloved daughter Cemile her loss is inestimable. Those of us who knew her well have lost a very dear friend.
  9 in total

Review 1.  Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.

Authors:  Jeffrey R Strawn; Laura Geracioti; Neil Rajdev; Kelly Clemenza; Amir Levine
Journal:  Expert Opin Pharmacother       Date:  2018-07       Impact factor: 3.889

Review 2.  Resolving the neural circuits of anxiety.

Authors:  Gwendolyn G Calhoon; Kay M Tye
Journal:  Nat Neurosci       Date:  2015-09-25       Impact factor: 24.884

3.  Benzodiazepine-induced spatial learning deficits in rats are regulated by the degree of modulation of α1 GABA(A) receptors.

Authors:  Srđan Joksimović; Jovana Divljaković; Michael L Van Linn; Zdravko Varagic; Gordana Brajković; Marija M Milinković; Wenyuan Yin; Tamara Timić; Werner Sieghart; James M Cook; Miroslav M Savić
Journal:  Eur Neuropsychopharmacol       Date:  2012-05-26       Impact factor: 4.600

4.  Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.

Authors:  Jonathan R T Davidson; Douglas E Feltner; Ashish Dugar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

5.  A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.

Authors:  Carl Gommoll; Suresh Durgam; Maju Mathews; Giovanna Forero; Rene Nunez; Xiongwen Tang; Michael E Thase
Journal:  Depress Anxiety       Date:  2015-04-17       Impact factor: 6.505

6.  Prevalence of and factors related to the use of antidepressants and benzodiazepines: results from the Singapore Mental Health Study.

Authors:  Mythily Subramaniam; Vincent Y F He; Janhavi A Vaingankar; Edimansyah Abdin; Siow Ann Chong
Journal:  BMC Psychiatry       Date:  2013-09-23       Impact factor: 3.630

7.  Anticholinergic and sedative drug burden in community-dwelling older people: a national database study.

Authors:  Catherine J Byrne; Caroline Walsh; Caitriona Cahir; Cristín Ryan; David J Williams; Kathleen Bennett
Journal:  BMJ Open       Date:  2018-07-06       Impact factor: 2.692

8.  A Durable Minimal Intervention Strategy to Reduce Benzodiazepine Use in a Primary Care Population.

Authors:  Stephen Davidson; Christine Thomson; Gordon Prescott
Journal:  Korean J Fam Med       Date:  2019-11-06

9.  Maternal use of sedative drugs and its effects on pregnancy outcomes: a Finnish birth cohort study.

Authors:  Satu-Maarit Björkstedt; Hannu Kautiainen; Ulla Tuomi; Mika Gissler; Pirjo Pennanen; Johan G Eriksson; Merja K Laine
Journal:  Sci Rep       Date:  2021-02-24       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.